Affordable Access

deepdyve-link
Publisher Website

Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.

Authors
  • Krasavin, Mikhail1
  • Lukin, Alexey2
  • Bagnyukova, Daria2
  • Zhurilo, Nikolay2
  • Zahanich, Ihor3
  • Zozulya, Sergey3, 4
  • 1 a Saint Petersburg State University , Saint Petersburg , Russian Federation. , (Russia)
  • 2 b Lomonosov Institute of Fine Chemical Technologies , Moscow Technological University , Moscow , Russian Federation. , (Russia)
  • 3 c Enamine Ltd. , Kyiv , Ukraine. , (Ukraine)
  • 4 d Taras Shevchenko National University , Kyiv , Ukraine. , (Ukraine)
Type
Published Article
Journal
Journal of Enzyme Inhibition and Medicinal Chemistry
Publisher
Informa UK (Taylor & Francis)
Publication Date
Dec 01, 2017
Volume
32
Issue
1
Pages
29–36
Identifiers
DOI: 10.1080/14756366.2016.1230110
PMID: 27781494
Source
Medline
Keywords
License
Unknown

Abstract

A series of nine compounds based on 3-[4-(benzyloxy)phenyl]propanoic acid core containing a 1-oxa-9-azaspiro[5.5]undecane periphery was designed, synthesized and evaluated as free fatty acid 1 (FFA1 or GPR40) agonists. The spirocyclic appendages included in these compounds were inspired by LY2881835, Eli Lilly's advanced drug candidate for type II diabetes mellitus that was in phase I clinical trials. These polar spirocyclic, fully saturated appendages (that are themselves uncharacteristic of the known FFA1 ligand space) were further decorated with diverse polar groups (such as basic heterocycles or secondary amides). To our surprise, while seven of nine compounds were found to be inactive (likely due to the decrease in lipophilicity, which is known to be detrimental to FFA1 ligand affinity), two compounds containing 2-pyridyloxy and 2-pyrimidinyloxy groups were found to have EC50 of 1.621 and 0.904 µM, respectively. This result is significant in the context of the worldwide quest for more polar FFA1 agonists, which would be devoid of liver toxicity effects earlier observed for a FFA1 agonist fasiglifam (TAk-875) in clinical studies.

Report this publication

Statistics

Seen <100 times